18095077

Source:http://linkedlifedata.com/resource/pubmed/id/18095077

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0030705, umls-concept:C0036525, umls-concept:C0220825, umls-concept:C0278701, umls-concept:C0332293, umls-concept:C0995188, umls-concept:C1514307, umls-concept:C1522484
pubmed:issue	4
pubmed:dateCreated	2007-12-20
pubmed:abstractText	The aim of the study was to evaluate whether the therapy-induced reduction of the (18)F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) maximum standardized uptake value in patients with advanced gastric adenocarcinoma treated with chemotherapy plus cetuximab could predict the objective response and outcome early during the treatment.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100886238
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorodeoxyglucose F18, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin, http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/cetuximab
pubmed:status	MEDLINE
pubmed:issn	1436-3291
pubmed:author	pubmed-author:CastellucciPaoloP, pubmed-author:Di FabioFrancescaF, pubmed-author:FantiStefanoS, pubmed-author:FunaioliChiaraC, pubmed-author:GiaquintaStefaniaS, pubmed-author:LongobardiCiroC, pubmed-author:MartoniAndrea AAA, pubmed-author:MutriVitaV, pubmed-author:PintoCarmineC, pubmed-author:Rojas LlimpeFabiola LFL, pubmed-author:SperandiFrancescaF
pubmed:issnType	Print
pubmed:volume	10
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	221-7
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:18095077-Adenocarcinoma, pubmed-meshheading:18095077-Adult, pubmed-meshheading:18095077-Aged, pubmed-meshheading:18095077-Antibodies, Monoclonal, pubmed-meshheading:18095077-Antineoplastic Agents, pubmed-meshheading:18095077-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18095077-Camptothecin, pubmed-meshheading:18095077-Clinical Trials, Phase II as Topic, pubmed-meshheading:18095077-Female, pubmed-meshheading:18095077-Fluorodeoxyglucose F18, pubmed-meshheading:18095077-Fluorouracil, pubmed-meshheading:18095077-Humans, pubmed-meshheading:18095077-Leucovorin, pubmed-meshheading:18095077-Male, pubmed-meshheading:18095077-Middle Aged, pubmed-meshheading:18095077-Positron-Emission Tomography, pubmed-meshheading:18095077-Predictive Value of Tests, pubmed-meshheading:18095077-Prospective Studies, pubmed-meshheading:18095077-Radiopharmaceuticals, pubmed-meshheading:18095077-Receptor, Epidermal Growth Factor, pubmed-meshheading:18095077-Remission Induction, pubmed-meshheading:18095077-Stomach Neoplasms, pubmed-meshheading:18095077-Treatment Outcome
pubmed:year	2007
pubmed:articleTitle	The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
pubmed:affiliation	Medical Oncology Unit, S. Orsola-Malpighi Hospital, Via Albertoni, 15-40138, Bologna, Italy.
pubmed:publicationType	Journal Article